Home
>
National Drug Code (NDC)
>
BARACLUDE
BARACLUDE - 0003-1614-12 - (entecavir)
Drug Information of BARACLUDE
| Product NDC: | 0003-1614 |
| Proprietary Name: | BARACLUDE |
| Non Proprietary Name: | entecavir |
| Active Ingredient(s): | .05 mg/mL & nbsp; entecavir |
| Administration Route(s): | ORAL |
| Dosage Form(s): | SOLUTION |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of BARACLUDE
| Product NDC: | 0003-1614 |
| Labeler Name: | E.R. Squibb & Sons, L.L.C. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA021798 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20050329 |
Package Information of BARACLUDE
| Package NDC: | 0003-1614-12 |
| Package Description: | 1 BOTTLE in 1 CARTON (0003-1614-12) > 210 mL in 1 BOTTLE |
NDC Information of BARACLUDE
| NDC Code | 0003-1614-12 |
| Proprietary Name | BARACLUDE |
| Package Description | 1 BOTTLE in 1 CARTON (0003-1614-12) > 210 mL in 1 BOTTLE |
| Product NDC | 0003-1614 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | entecavir |
| Dosage Form Name | SOLUTION |
| Route Name | ORAL |
| Start Marketing Date | 20050329 |
| Marketing Category Name | NDA |
| Labeler Name | E.R. Squibb & Sons, L.L.C. |
| Substance Name | ENTECAVIR |
| Strength Number | .05 |
| Strength Unit | mg/mL |
| Pharmaceutical Classes | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
